|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 14, 2017 ) Purpose of care diagnostics alludes to the tests conveyed at site of the patient care to give the prompt outcomes. These diagnostics enhance the infection administration and discovery. Irresistible sicknesses are caused by different microorganisms, for example, infection, microscopic organisms, growths, and parasites. Irresistible illness purpose of care diagnostics lessens the time between ailment testing and determination of a contamination. These days the vast majority of the irresistible sicknesses, for example, HIV, tuberculosis, flu, tropical ailments, and sexually transmitted contaminations are analyzed by the purpose of care testing. The real favorable circumstances with the purpose of care testing are lessened in finding time, postoperative care time, change in illness results, precision in results, and straightforward strategies for conclusion of the irresistible maladies.
Increase in the incidence and prevalence of infectious diseases such as malaria, dengue, HIV, rise in healthcare expenditure, growing investments from public and private sectors for the development of new products, rising government support towards the adoption of point of care devices are expected to drive global infectious disease point of care diagnostics market over the forecast period. Moreover, the technological advancements in point of care diagnostic devices and introduction of home-based point of care devices are also anticipated to boost the infectious disease point of care diagnostics market. However, reluctance among the patients to change in existing diagnostic practices, stringent regulatory policies, and reimbursement issues might restrain the growth of global infectious disease point of care diagnostics market over the forecast timeframe.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-infectious-disease-point-of-care-diagnostics-market/#ulp-4H8Z4LpNMLEuOnnx
The infectious disease point of care diagnostics market segmented based on product type, disease condition, prescription mode, and end users.
Based on product type, the infectious disease point of care diagnostics market segmented into the following:
• Infectious disease testing kits & Reagents
o Hepatitis
o HIV infection
o Respiratory infections
o Influenza
o Sexually-transmitted diseases (STDs) infection
o Others
• Haematology testing kits
• Urinalysis Testing Kits
• Others
Based on disease condition, the infectious disease point of care diagnostics market segmented into the following:
• Bacterial Infection
• Fungal infection
• Viral Infection
• Cardiovascular infection
• GI infections
• Sexually transmitted disease
• CNS infections
• Other
Based on prescription mode, the infectious disease point of care diagnostics market segmented into the following:
• Over-the-counter (OTC) Testing Kits
• Prescription-based Testing Kits
Based on end-user, the infectious disease point of care diagnostics market segmented into the following:
• Professional diagnostic centres
o Hospitals
o Outpatient healthcare Setting
• Homecare
• Others
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-infectious-disease-point-of-care-diagnostics-market/#ulp-c654SbFYO64MsOhu
The global infectious disease point of care diagnostics market is in the flourishing stage as several local and international players are actively involved in the development of infectious disease point of care diagnostic devices. Increase in the prevalence of the deadly infectious disease will drive the growth of the global infectious disease point of care diagnostics market. For instance, according to World Health Organisation, global health observatory (GHO) data, in 2013, approximately 34-38 million people suffered from HIV infection worldwide. Launching of new products, approvals from various regulatory bodies, acquisitions and mergers, partnerships, collaborations, and joint ventures are expected to fuel the growth of global infectious disease point of care diagnostics market over the forecast period. For instance, in January 2015, FDA has approved Alere for its first CLIA waiver for the nucleic acid-based test, Influenza A&B. Further Roche’s CLIA waiver for Cobas Liat System and Strep A. By 2016, many systems received CLIA waivers from FDA including the Xpert Flu/RSV Xc by Cepheid’s.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-infectious-disease-point-of-care-diagnostics-market/#ulp-14mlyhjMGhVjZqa3
Geographically, global infectious disease point of care diagnostics market has been segmented into following regions Viz. North America, Latin America, Europe, Middle East & Africa and Asia-Pacific. North-America holds a key share in global infectious disease point of care diagnostics market is due to increase in the prevalence of infectious diseases especially in U.S. (according to UNAIDS, in 2012, about 1.3Mn patients were diagnosed with HIV within the U.S.). These statistics are likely to increase over the coming years if suitable treatment options are not provided in time. The European region is also a major region for the growth of global infectious disease point of care diagnostics market due to improved healthcare infrastructure, and increase in prevalence of bacterial and viral diseases (according to WHO European Region, at the end of 2015, about 13.3 Mn people live with chronic hepatitis B, an estimated 15 Mn people with hepatitis C, and more than 2 Mn people with HIV). Moreover, Asia-Pacific region holds a significant growth in infectious disease point of care diagnostics market owing to the high prevalence of infectious diseases, unhygienic environment, and huge investment opportunities due to increase in healthcare expenditure. Moreover, due to high prevalence and incidence of infectious diseases especially sexually transmitted disease and bacterial infections, and high population – the growth of global infectious disease point of care diagnostics market expected to fuel in the Asia-Pacific region.
Some of the players in the global infectious disease point of care diagnostics market are Cepheid Inc. (Danaher Corporation) (U.S.), Abbott Laboratories, Inc. (U.S.), F. Hoffmann La Roche Limited (Switzerland), Beckman Coulter, Inc. (U.S.), Siemens AG (Germany), Johnson & Johnson Services, Inc. (U.S.), Instrumentation Laboratory (U.S.), Becton, Dickinson and Company (U.S.), Alere Inc. (U.S.), Nova Biomedical (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Quidel Corporation (U.S.) to name a few.
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
Precision Business Insights
Sales
+1-866-598-1553
sales@precisionbusinessinsights.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
